|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Popelková, P. Our experiences of treatment allergic rhinitis with
intranasal corticosteroid fluticasone furoate. Kazuistiky v alergologii,
pneumologii a ORL 6, č. 1: 4–6, 2009. |
|
|
 |
|
 |
|
|
|
|
|
|
The case history presents 42-year-old patient suffering allergic rhinitis
since he was 10 years old. He was successfully treated with new
intranasal corticosteroid – fluticasone furoate.
Key words: allergic rhinitis, bronchial asthma
|
|
|
|
|
|
|
|
|
|
Sedlák, V. The apparent failure of omalizumab for difficult-to-control
asthma. Kazuistiky v alergologii, pneumologii a ORL 6, č. 1: 8–10, 2009. |
|
|
|
|
|
|
|
|
|
|
|
GINA guidelines update established anti-IgE therapy for
patient with uncontrolled allergic asthma despite high dose of
anti-inflammatory medication, Anti-IgE is indicated especially for IgE
mediated asthma patients with decreased lung functions, everyday
frequent symptoms and exacerbations. Its effectiveness is evaluated
after 16 weeks of therapy. We present data of patient with severe
persistent uncontrolled allergic asthma with corticosteroid dependency
and fixed bronchial obstruction. Anti-IgE therapy led to improvement of
life-quality, decreased need of oral steroid bursts, however it did not
influenced exertional dyspnea which was most disturbing symptom.
Therefore patient refused continuing this treatment after 6 months.
Withdrawal of omalizumab led to worsening of symptoms, increased asthma
exacerbations and poor life quality. One year later was anti-IgE therapy
started again with the same results, patient is satisfied now.
Key words: difficult-to-control asthma, omalizumab,
comorbidities
|
|
|
|
|
|
|
|
|
|
Bartoň, P., Kerekes, Z., Dvořáková, R. Interesting bronchological (and
morphological) findings: Part 9 – Middle lobe syndrome. Kazuistiky v
alergologii, pneumologii a ORL 6, č. 1: 15–20, 2009. |
|
|
|
|
|
|
|
|
|
|
|
Key words: tuberculosis, flexible
bronchoscopy (FOB), bronchoscopic findings, middle lobe syndrome |
|
|
|
|
